京新药业
(002020)
| 流通市值：88.61亿 | | | 总市值：105.39亿 |
| 流通股本：7.24亿 | | | 总股本：8.61亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,208,743,897.71 | 2,149,921,275.37 | 1,060,660,180.25 | 3,998,835,219.87 |
| 营业收入 | 3,208,743,897.71 | 2,149,921,275.37 | 1,060,660,180.25 | 3,998,835,219.87 |
| 二、营业总成本 | 2,608,110,283.39 | 1,735,633,089.02 | 870,669,357.5 | 3,367,036,496.62 |
| 营业成本 | 1,568,830,620.06 | 1,041,122,206.89 | 510,338,395.36 | 1,976,488,431.24 |
| 税金及附加 | 34,319,963.51 | 22,617,821.03 | 10,138,702.59 | 46,745,308.14 |
| 销售费用 | 587,603,792.33 | 383,812,173.66 | 207,904,913.74 | 783,527,330.14 |
| 管理费用 | 194,483,465.65 | 127,714,184.38 | 52,083,952.53 | 213,168,211.63 |
| 研发费用 | 269,444,316.12 | 197,024,431.93 | 98,380,244.05 | 400,934,730.87 |
| 财务费用 | -46,571,874.28 | -36,657,728.87 | -8,176,850.77 | -53,827,515.4 |
| 其中:利息费用 | 7,258,253.21 | 6,094,129.7 | 3,737,540.65 | 7,314,834.56 |
| 其中:利息收入 | 57,501,060.04 | 41,610,562.03 | 11,743,911.24 | 60,269,451.18 |
| 加:公允价值变动收益 | 894,143.84 | 853,424.66 | 176,705.48 | 36,770,941.18 |
| 加:投资收益 | 5,969,548.08 | -132,060.33 | 1,793,438.35 | 6,440,588.27 |
| 资产处置收益 | 346,885.05 | 239,398.95 | 1,673.07 | 6,859,767.39 |
| 资产减值损失(新) | 101,627.74 | 1,409,155.4 | -1,934,674.71 | -21,145,432.43 |
| 信用减值损失(新) | -17,634,106.9 | -12,617,473.37 | -3,153,908.97 | -5,137,515.63 |
| 其他收益 | 81,503,553.5 | 72,130,233.36 | 15,179,922.22 | 58,471,887.63 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 671,815,265.63 | 476,170,865.02 | 202,053,978.19 | 714,058,959.66 |
| 加:营业外收入 | 7,571,629.08 | 4,707,447.17 | 177,638 | 2,471,375.58 |
| 减:营业外支出 | 2,922,596.43 | 756,402.16 | 114,336.88 | 8,489,543.29 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 676,464,298.28 | 480,121,910.03 | 202,117,279.31 | 708,040,791.95 |
| 减:所得税费用 | 95,904,869.65 | 74,251,591.08 | 28,905,146.7 | 84,623,219.09 |
| 六、净利润 | 580,559,428.63 | 405,870,318.95 | 173,212,132.61 | 623,417,572.86 |
| 持续经营净利润 | 580,559,428.63 | 405,870,318.95 | 173,212,132.61 | 623,608,462.8 |
| 终止经营净利润 | - | - | - | -190,889.94 |
| 归属于母公司股东的净利润 | 575,012,790.33 | 402,122,680.69 | 171,207,841.45 | 618,898,033.74 |
| 少数股东损益 | 5,546,638.3 | 3,747,638.26 | 2,004,291.16 | 4,519,539.12 |
| (一)基本每股收益 | 0.67 | 0.47 | 0.2 | 0.72 |
| (二)稀释每股收益 | 0.67 | 0.47 | 0.2 | 0.72 |
| 八、其他综合收益 | 206,930.55 | 385,583.07 | 284,399.46 | -333,762.92 |
| 归属于母公司股东的其他综合收益 | 206,537.51 | 381,592.86 | 274,282.49 | -333,902.34 |
| 九、综合收益总额 | 580,766,359.18 | 406,255,902.02 | 173,496,532.07 | 623,083,809.94 |
| 归属于母公司股东的综合收益总额 | 575,219,327.84 | 402,504,273.55 | 171,482,123.94 | 618,564,131.4 |
| 归属于少数股东的综合收益总额 | 5,547,031.34 | 3,751,628.47 | 2,014,408.13 | 4,519,678.54 |
| 公告日期 | 2024-10-25 | 2024-08-15 | 2024-04-24 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |